• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

Contrast makers cut patent deal

Article

Epix Medical has granted Bracco Imaging a worldwide, nonexclusive, royalty-bearing license for the use of certain patents. The $10 million deal covers patents related to Bracco’s Multihance, which is used to image the liver and central nervous

Epix Medical has granted Bracco Imaging a worldwide, nonexclusive, royalty-bearing license for the use of certain patents. The $10 million deal covers patents related to Bracco’s Multihance, which is used to image the liver and central nervous system. In May 2000, Epix granted Schering a worldwide, nonexclusive, royalty-bearing license for the sale of Eovist, an investigational MRI contrast agent for liver imaging. The patents are owned by the Massachusetts General Hospital and licensed exclusively to Epix, which will receive upfront payments made up of a license fee, royalties on past sales, prepayment of future royalties, and a contingent license fee based on marketing approval of Multihance in the U.S.

Recent Videos
Emerging Research at SNMMI Examines 18F-flotufolastat in Managing Primary and Recurrent Prostate Cancer
Could Pluvicto Have a Role in Taxane-Naïve mCRPC?: An Interview with Oliver Sartor, MD
New SNMMI President Cathy Cutler, PhD, Discusses Current Challenges and Goals for Nuclear Medicine
Where the USPSTF Breast Cancer Screening Recommendations Fall Short: An Interview with Stacy Smith-Foley, MD
A Closer Look at MRI-Guided Transurethral Ultrasound Ablation for Intermediate Risk Prostate Cancer
Improving the Quality of Breast MRI Acquisition and Processing
Can Fiber Optic RealShape (FORS) Technology Provide a Viable Alternative to X-Rays for Aortic Procedures?
Does Initial CCTA Provide the Best Assessment of Stable Chest Pain?
Making the Case for Intravascular Ultrasound Use in Peripheral Vascular Interventions
Can Diffusion Microstructural Imaging Provide Insights into Long Covid Beyond Conventional MRI?
Related Content
© 2024 MJH Life Sciences

All rights reserved.